Publication:
Assessing the Safety of Human Pluripotent Stem Cells and Their Derivatives for Clinical Applications

dc.contributor.authorPeter W. Andrewsen_US
dc.contributor.authorUri Ben-Daviden_US
dc.contributor.authorNissim Benvenistyen_US
dc.contributor.authorPeter Coffeyen_US
dc.contributor.authorKevin Egganen_US
dc.contributor.authorBarbara B. Knowlesen_US
dc.contributor.authorAndras Nagyen_US
dc.contributor.authorMartin Peraen_US
dc.contributor.authorBenjamin Reubinoffen_US
dc.contributor.authorPeter J. Rugg-Gunnen_US
dc.contributor.authorGlyn N. Staceyen_US
dc.contributor.otherUniversity of Sheffielden_US
dc.contributor.otherBroad Instituteen_US
dc.contributor.otherHebrew University of Jerusalemen_US
dc.contributor.otherUCL Institute of Ophthalmologyen_US
dc.contributor.otherUniversity of California, Santa Barbaraen_US
dc.contributor.otherHarvard Universityen_US
dc.contributor.otherHarvard Stem Cell Instituteen_US
dc.contributor.otherJackson Laboratoryen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherMount Sinai Hospital of University of Torontoen_US
dc.contributor.otherMonash Universityen_US
dc.contributor.otherUniversity of Melbourneen_US
dc.contributor.otherThe Florey Institute of Neuroscience and Mental Healthen_US
dc.contributor.otherWalter and Eliza Hall Institute of Medical Researchen_US
dc.contributor.otherHadassah University Medical Centreen_US
dc.contributor.otherThe Babraham Instituteen_US
dc.contributor.otherWellcome Trust - Medical Research Council Cambridge Stem Cell Instituteen_US
dc.contributor.otherMedicines and Health Care products Regulatory Agencyen_US
dc.date.accessioned2018-12-21T06:46:07Z
dc.date.accessioned2019-03-14T08:02:51Z
dc.date.available2018-12-21T06:46:07Z
dc.date.available2019-03-14T08:02:51Z
dc.date.issued2017-07-11en_US
dc.description.abstract© 2017 Pluripotent stem cells may acquire genetic and epigenetic variants during culture following their derivation. At a conference organized by the International Stem Cell Initiative, and held at The Jackson Laboratory, Bar Harbor, Maine, October 2016, participants discussed how the appearance of such variants can be monitored and minimized and, crucially, how their significance for the safety of therapeutic applications of these cells can be assessed. A strong recommendation from the meeting was that an international advisory group should be set up to review the genetic and epigenetic changes observed in human pluripotent stem cell lines and establish a framework for evaluating the risks that they may pose for clinical use.en_US
dc.identifier.citationStem Cell Reports. Vol.9, No.1 (2017), 1-4en_US
dc.identifier.doi10.1016/j.stemcr.2017.05.029en_US
dc.identifier.issn22136711en_US
dc.identifier.other2-s2.0-85021993873en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/41846
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85021993873&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.titleAssessing the Safety of Human Pluripotent Stem Cells and Their Derivatives for Clinical Applicationsen_US
dc.typeConference Paperen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85021993873&origin=inwarden_US

Files

Collections